Drug Trial Radar · NCT07138547
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 26, 2025
Primary completion
Aug 31, 2028
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Targeted therapy against the CD30 molecule has achieved some progress in CD30-positive Hodgkin lymphoma, but its efficacy remains unsatisfactory. Previous studies have demonstrated that N-glycan modifications in the extracellular domain of target proteins can disrupt immune synapse formation with CAR-T cells. Our preliminary research has shown that ablation of N-glycans on CD30 enhances the anti-tumor effect of CD30-targeted therapy.It is hypothesized that Eliglustat, by inhibiting GSL synthesis,may potentiate the anti-tumor effect. Consequently,we designed and initiated a single-center, open-label phase I/II clinical study to evaluate the efficacy and feasibility of Eliglustat combined with CD30 targeted immunotherapy in patients with CD30-positive lymphoma. The primary endpoint of this study is the safety and efficacy of Eliglustat combined with CD30 targeted therapies.
Conditions
- Lymphoma
Interventions
Eliglustat, CD30 target immunotherapyDrug
Eliglustat 63mg will be administered twice daily in the first 14 days and the following every other week. CD30 target immunotherapy:Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with treatment-related adverse events (AEs)Time frame: Up to 120 days after the last dose of study drugs]
- CR rate (CRR) in the CAR-T cell plus Eliglustat treatment groupTime frame: 12 months
- Progression-free survival (PFS) in the BV plus Eliglustat treatment group.Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
People's Liberation Army General Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.